Instil Bio discontinues AXN-2510, pivots to acquisitions; cash $76.3M

Instil Bio, Inc.

Discontinued clinical development of AXN-2510; terminated license with ImmuneOnco.
Cash, equivalents & marketable securities $76.3M as of Dec 31, 2025, down from $115.1M year-end 2024.
Management evaluating acquisitions and in-licensing opportunities across therapeutic areas.
Net loss per share (GAAP) $1.21 for Q4 2025; full year net loss $10.70 per share.
Cash expected to fund operating plan beyond 2027.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Instil Bio, Inc. reported the fourth quarter and full year ended December 31, 2025 results: net income Net loss per share, basic and diluted was $1.21 and $10.70 for the fourth quarter and full year ended December 31, 2025,, EPS Net loss per share, basic and diluted was $1.21 and $10.70 for the fourth quarter and full year ended December 31, 2025,.

Period: the fourth quarter and full year ended December 31, 2025
Net income: Net loss per share, basic and diluted was $1.21 and $10.70 for the fourth quarter and full year ended December 31, 2025,
EPS: Net loss per share, basic and diluted was $1.21 and $10.70 for the fourth quarter and full year ended December 31, 2025,
Result: reported results

Exact text from the filing

On March 27, 2026, Instil Bio, Inc. (the “Company”) issued a press release providing a corporate update and announcing its financial results for the fourth quarter and full year ended December 31, 2025

View on SEC.gov

Browse all earnings releases →

Instil Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001789769-26-000018

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.